STUDY QUESTION: Could aromatase inhibitors (AI) be used to reduce risks of uterine endometrial cancer growth or recurrence during ovarian stimulation?
Introduction
Uterine endometrial cancer is one of the very common types of cancer in women. In the USA, for example, there were 54 870 cases in 2015, including 10 170 deaths, and these numbers have been increasing in recent years (Siegel et al., 2015) . The standard treatment for uterine endometrial cancer is the combination of surgery, chemotherapy and radiotherapy (Rutledge, 1974; Signorelli et al., 2009) , but young patients with early stage cancer (equivalent to the International Federation of Gynecology and Obstetrics stage IA) or endometrial hyperplasia sometimes request consideration of fertility preservation. In countries where surrogate pregnancy is recognized, women can have children by surrogate pregnancy after total hysterectomy, including bilateral adnexectomy so long as the collection of oocytes is performed before surgery (Azim and Oktay, 2007) . However, for patients who do not have the option of surrogate pregnancy, fertility preservation implies conception by patient's own uterus and is associated with higher risks. For those patients, endometrial curettage is initially performed to physically remove cancer or hyperplasia cells, followed by hormone therapy.
Uterine endometrial cancer is classified as the estrogen-dependent type I and estrogen-independent type II. The former represents more than 80% of cases, and its carcinogenesis is associated with estrogen (Setiawan et al., 2013) . Progesterone therapy has been demonstrated as an effective treatment for type I uterine endometrial cancers (Kelley and Baker, 1961) . When medroxyprogesterone acetate (MPA) was used for the treatment of endometrial cancer and atypical endometrial hyperplasia, the overall complete response (CR) rate was 67%, hence, treatment with MPA has become the standard approach for patients who choose not to undergo hysterectomy to preserve fertility potential (Ushijima et al., 2007) .
In premenopausal women, estrogen is synthesized primarily in the ovaries. In postmenopausal women, the estrogen level decreases as ovarian function declines and estrogen production relies on synthesis from androgens in the adrenal glands by the enzymatic reaction of aromatase. Estrogen is also produced from androgens in the aromatase pathway through the interaction of tumors and interstitial cells (Takahashi-Shiga et al., 2009) . Aromatase inhibitors (AI) inhibit the enzymatic activity of aromatase and thus suppresses estrogen biosynthesis.
Recurrence and mortality rates of estrogen receptor (ER)-positive early breast cancer are reduced by long-term AI administration, which is more effective than the selective ER modulator tamoxifen (Early Breast Cancer Trialists' Collaborative Group, 2015) . Therefore, AI have been used as long-term hormone therapy for breast cancer.
Ovarian stimulation elevates blood estrogen to non-physiological levels for limited periods by promoting the development of oocytes. Although, the short-term rise of blood estrogen caused by ovarian stimulation has been reported not to increase the risk of developing breast cancer in general population (Venn et al., 1999; Silva Idos et al., 2009) , co-administration of AI for ovarian stimulation in patients with breast cancer is recommended due to the potential risk of cancer recurrence (Reddy and Oktay, 2012; Oktay et al., 2015; Rodgers et al., 2017) .
Concomitant AI use has been previously investigated for ovarian stimulation in patients with endometrial cancer for similar reasons (Azim and Oktay, 2007) , however, reported cases are limited and surrogate pregnancy is recommended.
Given the lack of evidence, in this experimental animal study we aimed to investigate the efficacy and safety of concomitant AI use by evaluation of tumor growth and blood estrogen concentrations as well as ovulation, insemination and embryo maturation under the internal use of AI.
Materials and Methods

Ethical approval
This study was performed upon the approval by the Animal Experiment Review Committee of St. Marianna University School of Medicine.
Animals
Mice were kept at 23 ± 2°C with a humidity of, 55 ± 5% humidity, 12-h light and 12-h dark cycle, and constant ad libitum access to feed food and water.
AI administration for estrogen measurements C57BL/6 J, 4-week-old, female mice (Japan SLC, Inc., Shizuoka, Japan) (N = 16) were divided into four groups. Using a gastric tube, the thirdgeneration AI letrozole (Femara ® ; Novartis Pharmaceuticals, AG, East Hanover, NJ) was administered at 0, 2, 10 or 25 μg/kg for 3 consecutive days. On the second day of letrozole administration, 7 IU of pregnant mare serum gonadotropin (PMSG; ASKA Animal Health Co., Ltd., Tokyo, Japan) was intraperitoneally administered to induce follicular development.
Measurement of the serum estrogen concentration
Mice were euthanized using carbon dioxide (CO 2 ) 2 days after the administration of PMSG. The blood was collected from their hearts, and centrifuged for 5 min at 684 g at 4°C in a 1.5-ml microtube. Supernatant serum was transferred to a 1.5-ml microtube and stored in a freezer. Serum 17β-estradiol (E2) concentrations were measured using an Estradiol EIA Kit (Cayman Chemical Co., Ltd, Ann Arbor, MI) in accordance with the manufacturer's protocol.
AI administration and ovarian stimulation
For four groups of C57BL/6 J, 4-week-old, female mice (N = 36), letrozole was orally administered at 0, 2, 10 or 25 μg/kg/day for 4 days. On Day 2 of the letrozole administration, 7 IU of PMSG was intraperitoneally administered to induce follicular development, and on Day 4, of the letrozole administration, 7 IU of hCG (ASKA Pharmaceutical Co., Ltd, Tokyo, Japan) was intraperitoneally administered to induce hyperovulation.
Harvesting cumulus oocyte complexes
Mice were euthanized 16 h after hCG administration, and cumulus oocyte complexes (COCs) were collected through an incision made in the ampulla of the Fallopian tube. Collected COCs were transferred to 100-μl TYH (LSI Medience Corp., Tokyo, Japan) culture drops covered with mineral oil (Irvine Scientific, Santa Ana, CA), and then cultured at 37°C under 5% CO 2 in air until insemination. Fertilized oocytes and embryos were cultured in the KSOM-AA medium (Merck Millipore Corp., Billerica, MA).
Sperm collection and pre-culture
Caudal parts of the epididymis were collected from 8-week-old to 12-week-old, male C57BL/6 J mice, and washed with the M16 culture medium (Global Stem, Rockville, MD). Blood and fat were removed on filter paper, and the sperm mass was collected from the tip of the caudal parts of the epididymis using a 23-G syringe needle. Then the collected sperm mass was submerged in 500 μl of the TYH medium in a 1.5-ml microtube and pre-cultured at 37°C and 5% CO 2 in air.
IVF and embryo culture
A 10-μl pre-cultured sperm was collected from the upper layer, and transferred to a TYH culture drop containing COCs and kept at 37°C under 5% CO 2 for 5-6 h to facilitate fertilization. After fertilization, ova were recovered from the TYH culture drops, transferred to drops of the KSOM medium, and cultured at 37°C, under 5% CO 2 in air. After culture for 16 h, two-cell embryos were transferred to fresh KSOM medium drops, and cultured at 37°C under 5% CO 2 to observing development up to the blastocyst stage.
Preparation and hematoxylin-eosin staining of mouse ovary tissue sections
Collected mouse ovaries were submerged in Bouin's solution (Wako Pure Chemical Industries, Ltd., Osaka, Japan) for 24 h at 4°C and saturated with paraffin by sequentially submerging them in the following: 70% v/v ethanol at room temperature for 1 h, 90% v/v ethanol at room temperature for 1 h, 100% ethanol at room temperature for 30 min, xylene at room temperature for 30 min, a mixture of paraffin and xylene at 65°C for 24 h, and paraffin at 65°C. Sequential 6-μm thick sections were prepared. Next, the paraffin sections were melted at 65°C, followed by deparaffinization with xylene, 100% ethanol, 90% v/v ethanol and 70% v/v ethanol. Tissue sections were stained with hematoxylin-eosin (HE), mounted, dried and evaluated.
Histological evaluation of ovaries
Histological evaluation of ovarian tissues was performed after HE staining. In ovaries collected during ovum collection and IVF, numbers of luteinized unruptured follicles (LUFs) were counted to evaluate any effects on the numbers of oocytes ovulated. Only nucleated ova were counted to avoid double counting.
Xenografting
The Ishikawa 3-H-12 cell line (National Research and Development Foundation JCRB Cell Bank, Osaka, Japan) (Nishida et al., 1996) , a cell strain expressing ER and progesterone receptor (PR), was used. Cells were cultured in minimum essential medium (Gibco Earle's salts + and Lglutamine; Thermo Fisher Scientific, Inc., Waltham, MA), with 15% w/v fetal bovine serum (Bovogen Biologicals Pty., Ltd, East Keilor, Australia) and 1% w/v Gibco Antibiotic-Antimycotic (Thermo Fisher Scientific, Inc., Waltham, MA). BALB/cSlc-nu/nu nude, 6-week-old, female mice (Japan SLC, Inc., Shizuoka, Japan) (N = 40) were used. We subcutaneously transplanted 1.0 × 10 7 Ishikawa 3-H-12 cells in the center of the mice's back using a 1-ml syringe with a 21-G syringe needle. Transplantation sites were monitored for 2 weeks to confirm grafting of the tumor. Four groups of 10 mice each were assigned to the following treatments.
Schedule for ovarian stimulation and AI administration
Group 1: Control group (no ovarian stimulation) No drug administration after transplantation (oral and intraperitoneal injections of the physiological saline). Bilateral ovariectomy was performed 2 weeks after transplantation. Starting 2 weeks after transplantation, intraperitoneal administrations of PMSG and hCG, once per week for 6 weeks.
For ovarian stimulation, follicular development was induced by intraperitoneal injection of 7-IU PMSG (ASKA Animal Health Co., Ltd). Hyperovulation was induced 2 days later by an intraperitoneal injection of 7-IU hCG (ASKA Animal Health Co.). Femara ® (2.5-mg tablet; Novartis Pharmaceuticals, AG) was pulverized using a mortar and pestle and dissolved in sterilized water. A 25 μg/kg was administered orally using a gastric tube. Sizes of subcutaneous tumors were measured weekly using a caliper with a vernier dial, and measurements in mm 3 (length × width × height)
were recorded. On Day 4 of the sixth week after starting ovarian stimulation, mice were euthanized 2 days after PMSG administration using CO 2 , tumors were excised, and bloods samples were collected.
Tumor evaluation and measurement of blood E2 concentration (i) After euthanasia of mice using CO 2 , blood was collected from their hearts, and the blood 17β-estradiol level was measured using the Estradiol EIA Kit (Cayman Chemical Co.). (ii) Tumors on body surfaces were photographed. (iii) Tumors were excised, photographed and weighed. (iv) Each excised tumor was cut into at least four pieces. Two pieces were placed in a 1.5-ml microtube and then stored at −80°C. ERα and ERβ expression levels of each tumor tissue were measured by reverse transcription real-time polymerase chain reaction (RT-rPCR). (v) Half of the remaining pieces were fixed using the Bouin solution, followed by HE staining. (vi) Remaining pieces were fixed using a neutral formalin solution, followed by Ki67 staining.
Statistical analysis
Results are expressed as the mean ± standard error of the mean. The effects of treatment were compared among the groups using one-way analysis of variance with the post-hoc Tukey honestly significant difference test. Differences were considered significant if P was < 0.05. All analyses were computed using SAS JMP Pro 12.2.0 (SAS Institute Inc., Cary, NC).
Results
Reduction of blood E2 level by letrozole
The effect of AI on the blood estrogen concentration was examined using letrozole. Increasing concentrations of letrozole were administered orally for 3 days in C57BL/6 J, female, 4-week-old mice (N = 16). The blood E2 concentration decreased from 29.0 ± 6.0 pg/ml to 25 ± 2.7, 11.4 ± 4.4 and 0.71 ± 0.4 pg/ml dose dependently with increasing concentrations of 2, 10 and 25 μg/kg of letrozole, respectively (Fig. 1 ). Significant decreases were obtained by 10 and 25 μg/kg of letrozole (P < 0.05).
Ovarian stimulation and letrozole administration
The effect of reduced E2 levels due to letrozole administration on superovulation for IVF was investigated. C57BL/6 J, female, 4-weekold mice (N = 36) were divided into four groups that received 0, 2, 10 or 25 μg/kg of letrozole orally. The numbers of retrieved oocytes in the 0, 2, 10 and 25-μg/kg letrozole groups were 48 ± 2.8, 50 ± 1.8, 39 ± 2.7 and 36 ± 4.1, respectively. Therefore, retrieved oocytes were significantly fewer in the 25-μg/kg group than in the control group (P < 0.05; Fig. 2A) . Fertilization rates were 79.9 ± 3.6%, 80.6 ± 4.1%, 74.7 ± 8.9% and 69.4 ± 5.3%, respectively, in the 0, 2, 10 and 25 μg/kg groups with no significant differences (P > 0.05; Fig. 2B ). Blastocyst achievement rates were 94.7 ± 1.3%, 97.0 ± 1.3%, 90.6 ± 3.9% and 89.5 ± 3.6%, respectively, in the 0, 2, 10 and 25-μg/kg groups, demonstrating no significant differences (P > 0.05; Fig. 2C ). Numbers of LUFs in ovarian tissue sections at the time of IVF were 5 ± 1.5, 3 ± 0.9, 2 ± 0.3 and 4 ± 0.9, respectively, in the 0, 2, 10 and 25-μg/kg letrozole groups. No correlation was observed between LUFs numbers and AI dose (P > 0.05; Fig. 2D ).
Suppression of uterine endometrial cancer growth by letrozole
Ishikawa 3-H-12 cells (1 × 10 7 ) were transplanted subcutaneously in the back of BALB/cSlc-nu/nu mice. After 2 weeks, 40 mice were divided into four groups and treated as described in Fig. 3 . Tumor size increased significantly in the ovarian stimulation group compared to the control group and was reduced by letrozole administration (Fig. 4) . The blood E2 concentration, similar to the result with female C57BL/ 6 J mice (Fig. 1) , was significantly lower in the letrozole and ovariectomy groups than in the ovarian stimulation group in BALB/cSlc-nu/ nu mice (P < 0.05; Fig. 5A ). As measured by RT-rPCR, the ERα messenger RNA expression level in tumor tissue was significantly higher in the ovarian stimulation group than in the other three groups (P < 0.05, Fig. 5B ). No significant differences in the ERβ expression level were found between any of the four groups (P > 0.05, Fig. 5B ).
Tumor tissues in all groups, after HE staining, showed characteristics of endometrial adenocarcinoma, including the formation of ductal structures, nuclear stratification with mild atypia, and cribriform pattern in the periductal region (Fig. 6A ). In addition, Ki67 stainingpositive cells were found in all groups (Fig. 6B) .
Discussion
The present study demonstrated that the growth of endometrial cancer cells was promoted during ovarian stimulation and suppressed by letrozole in correlation with blood estrogen levels.
In general, long-term exposure to unopposed estrogen increases the incidence of endometrial cancer (Weiderpass et al., 1999) . On the other hand, no increase in the incidence of hormone-sensitive tumors due to ovarian stimulation has been reported in the general population (Venn et al., 1999; Silva Idos et al., 2009) . This is because Mice were divided into four groups according to the doses of letrozole (0, 2, 10 and 25 μg/kg). Letrozole was given orally for 3 days. A 7 IU of pregnant mare serum gonadotropin (PMSG) was given i.p., 2 days after the letrozole administration. All mice were sacrificed 2 days after PMSG administration, and E2 concentrations in sera were measured. *P < 0.05 versus the control. days. Pregnant mare serum gonadotropin and human chorionic gonadotropin were administered at seven IU/mouse intraperitoneally on Days 2 and 4, respectively, after AI administration. IVF was performed on Day 5 after AI administration. *P < 0.05 versus the control.
the development of cancer is a long-term process in which mutations accumulate in genes such as tumor suppressor genes and mismatch repair genes while endometrial cells repeat cell divisions under stimulation by estrogen (Banno et al., 2014) . On the other hand, the increase in blood estrogen levels due to ovarian stimulation and accompanying follicular development is usually a temporary environmental change. This study was undertaken to examine whether a short-term increase in blood estrogen concentrations contributes to the proliferation of a small number of established endometrial cancer cells, as predicted from Mice were euthanized in all groups for blood collection and tumor dissection Group1 Control Group2 Ovarian stimulation Group3 Ovarian stimulation + daily AI administration Group4 Ovariectomy + ovarian stimulation Figure 3 Experimental schedules of treatments started 2 weeks after tumor xenografting in all four groups. Group 1: no treatment; group 2: weekly intraperitoneal injections of 7 IU/mouse of pregnant mare serum gonadotropin, followed by intraperitoneal injections of 7 IU/mouse hCG 2 days later; Group 3: ovarian stimulation with daily oral administration of 25 μg/kg of the aromatase inhibitor; and Group 4: ovariectomy and ovarian stimulation 2 weeks after xenograft placement. past xenograft experiments (Clarke and Satyaswaroop, 1985) . As it is difficult to reproduce residual endometrial cancer cells remaining in the uterus after endometrial curettage and MPA therapy in animal experiments, risks of clinical recurrence were approximately evaluated by implanting a small number of tumor cells subcutaneously in nude mouse and observing proliferation of these tumor cells. In the present study, we demonstrated that ovarian stimulation as a risk factor for endometrial cancer growth or recurrence and that the AI use is beneficial during ovarian stimulation against hormone-sensitive endometrial cancer growth. Letrozole reduced the blood E2 concentration dose dependently (Fig. 1) , without apparent effects on embryo development (Fig. 2C) . However, the oocyte yield decreased at the highest dose of letrozole in the 25 μg/kg group as compared to the control group ( Fig. 2A) . Since no correlation was observed between LUF number and AI doses (Fig. 2D) , the decrease in the number of oocytes retrieved did not appear to be due to dysfunction in ovulation; instead it appeared to be caused by effects on the maturation process of oocytes. In clinical practice, trigger timing by hCG or gonadotropin-releasing hormone agonist is determined by measuring the diameter of leading follicles. Since it was difficult to measure follicle sizes in mouse experiments, our experimental protocol, in which the same dose of hCG was administered 48 h after PMSG administration in all groups, may have affected the number of oocytes yielded. Since no significant decreases in oocyte yields nor risks on embryogenesis have been reported with AI administration in clinical studies (Oktay et al., 2005; Tulandi et al., 2006; Lee and Oktay, 2012; Rodgers et al.,2017) , this could be due to the use of prolific animals such as mice. Although further studies are required for the impact of high dose AI uses on folliculogenesis, AI appears not to have serious effects on the fertilization or embryo development.
Based on the present study, ER α expression, was highest in the ovarian stimulation group than in the other three groups (Fig. 5B) , which is consistent with a previous report that E2 acts on ER α, inducing c-Fos expression and thus cell proliferation (Vivacqua et al., 2006) . The proliferative and prognostic indicator Ki67 staining did not change significantly in the present study (Fig. 6B) , although it was previously shown to correlate with the suppression of endometrial cancer growth by neoadjuvant anastrozole treatment (Thangavelu et al., 2013) . Loci that showed strong Ki67-staining were uneven in all tumors, indicating complexities of tumors where proliferation and necrosis occurred even in the same tumor mass and which could have caused Ki67 staining irrespective of proliferation rates.
Previous reports on the therapeutic effect of AI against endometrial cancer are unclear. A phase II clinical study, in which 23 patients with recurrent uterine endometrial cancers were treated by the administration of anastrozole (a third-generation AI) showed minimal therapeutic effect (Rose et al.,2000) . In another study of 28 postmenopausal women with advanced or recurrent uterine endometrial cancer treated with letrozole, the overall response rate was 9.4% and the authors concluded that letrozole was well tolerated but had little overall activity (Ma et al., 2014) . Recently, researchers reported that AI was effective against low-grade endometrial cancer after failure with progesterone treatment in three cases (Straubhar et al., 2017) . These reports indicate that AI may have therapeutic effect only for a limited number of ER-positive endometrial cancer cases, suggesting the diverse developmental mechanisms of endometrial cancer.
As our results are based on one type of endometrial cancer cell line, we cannot conclude that the concomitant AI use is effective for fertility preservation treatment of all endometrial cancer or hyperplasia patients, since it is currently not possible to fully identify the nature of the tumor in each case.
Since fertility preservation treatments for endometrial cancer or hyperplasia with atypia involve potential major risks which cannot be ignored, concomitant AI use during ovarian stimulation is worth considering to minimize those risks. In fact, there were cases in our institution in which endometrial cancer recurred after the ovarian stimulation during MPA therapy, resulting in patient death, although the causal relationship is unknown. Our research is motivated by these difficult experiences.
We focused on the ovarian stimulation in this study, but the influence of estrogen rise during pregnancy period on endometrial cancer or hyperplasia is also controversial. Regarding this point, the rise of progesterone and so-called healthy mother effect should be also taken into consideration (Valachis et al., 2010) .
Conclusion
Ovarian stimulation is a potential option for fertility preservation in reproductive age women with low-grade endometrial cancer or endometrial hyperplasia. It is however associated with risks of their recurrence or growth which can be mitigated by the concomitant AI use by decreasing serum estrogen concentrations. 
